Recent Winners

Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.



Trading Lessons

Mainstream Financial News


Nektar Therapeutics NKTR-181 meets Primary and Secondary Endpoints in Phase 3

March 20, 2017: Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction (Read More….)

Sell Exact Sciences For a 55% Win!

March 4, 2017: Sell Exact Sciences for a 55% win in 37 days. Congratulations if you were able to make money on the trade and always remember to sell your positions before you get the sell alert from me. I review more than 200 open stock positions over the weekend when I have time and (Read More….)

Sell Global Blood Therapeutics For a Huge 91% Win!

March 4, 2017: Sell Global Blood Therapeutics for a monster 91% win in 41 days! Congratulations if you were able to make money on the trade.

January 4, 2017: JPMorgan Chase initiates coverage of biotechnology firm Global Blood Therapeutics with an Overweight rating and a price target of $25. JPMorgan thinks GBT440 is a (Read More….)

Celgene Announces Positive Results from Phase III Trial of Oral Ozanimod

February 17, 2017: Celgene announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex).

SUNBEAM evaluated two (

Protalix Biotherapeutics For a Monster 180% Win!

February 11, 2017: Sell Protalix Biotherapeutics for a monster 180% win! This is our biggest winner to date. Long upper shadow and Inverted Hammer candlestick are usually good take profit signals. Congratulations if you made money on the trade.

December 27, 2016: Protalix Biotherapeutics announced today the confirmation of the recent letter of intent to (Read More….)

Centene Beats on Earnings and Revenue

February 7, 2017: Centene reports Q4 EPS of $1.19 versus the $1.12 estimate. Revenue also beat coming in at $11.9 billion versus the $10.9 billion estimate. Quarter-end at-risk managed care membership came in at 11.44 million versus 5.1 million last year representing an increase of 223% YoY, nice!

January 5, 2017: Centene Corporation announced (

Abbott Laboratories Announces FDA Approval For Assurity MRI Pacemaker

February 1, 2017: Abbott Laboratories announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the Assurity MRI pacemaker and the Tendril™ MRI pacing lead. Patients implanted with these low-voltage devices will have the ability to undergo full body magnetic resonance imaging (MRI) scans, if required. With the approval, the (Read More….)

Ironwood Pharmaceuticals Reports Positive Top-Line Results from Phase III Linaclotide Trial

January 29, 2017: Astellas Pharma and Ironwood Pharmaceuticals announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint.

Linaclotide is approved in Japan as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C). Linaclotide is (Read More….)’s Feuerstein Says Celgene Should Buy Biogen

January 23, 2017:’s Feuerstein says Celgene should considering buying Biogen. Source:

January 13, 2017: Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. (Read More….)

Hain Celestial Seeing Heavy Call Activity

January 20, 2017: Seeing heavy call activity on Hain Celestial. February calls are active again at more than 8x average daily volume.

December 12, 2016: Hain Celestial Group is coming off of a double bottom on takeover rumors that are circulating. The rumor is that GIS could be a possible suitor. Takeover rumors have been (Read More….)

AbbVie Gets FDA Approval For Imbruvica

January 19, 2017: AbbVie announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This indication is approved under accelerated approval based on overall response rate (ORR), and (Read More….)

Avondale Partners Raised McKesson To Market Outperform

January 17, 2017: Avondale Partners raised McKesson to Market Outperform from Market Perform.

January 17, 2017: McKesson agrees to $150 million settlement with DOJ over failure to report suspicious orders of drugs. The nationwide settlement requires McKesson to suspend sales of controlled substances from distribution centers in Colorado, Ohio, Michigan and Florida for multiple years. (Read More….)

Top Performing GuerillaStockTrading Picks For Week Ending January 13 2017

Orexigen Therapeutics continues to be the top performing stock since profiled on Orexigen Therapeutics is up an incredible +74.59%.

Here are the top performing stocks on for the week ending January 13, 2017.

OREX = +74.59% XGTI = +46.26% LPTH = +25.71% EXAS = +24.64% RNVA = +22.22% IMGN = +20.59% OPGN (Read More….)

Novo Nordisk Marketing Authorization Granted by European Commission For Fiasp

January 10, 2017: Novo Nordisk A/S B announces marketing authorization granted by European Commission for Fiasp for treatment of diabetes in adults. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017. The authorisation covers all 28 European Union member states.

Fiasp is the brand name for fast-acting (

Huron Consulting Group Oversold Doji On Acquisition of Pope Woodhead & Associates

January 9, 2017: Huron Consulting Group formed a doji today, in oversold territory, on news it acquired Pope Woodhead & Associates. Huron Consulting Group says that it has expanded its life sciences strategy expertise with the acquisition of Pope Woodhead & Associates. The UK-based consulting firm provides market access capabilities to assist clients in developing (Read More….)

PTC Therapeutics Breaks Above 200 MA On Positive CHMP Opinion

January 9, 2017: Biotechnology firm PTC Therapeutics’ stock broke above the 200 day MA today as it received notification from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna (ataluren). The positive decision is based on the recent renewal recommendation by the Committee (Read More….)

JMP Securities Raised Zafgen To Market Outperform

January 8, 2017: On January 5, 2017, JMP Securities raised biotechnology firm Zafgen to Market Outpeform from Market Perform, and set a price target of $8. JMP Securities expects positive Phase 1 results for ZGN-1061 to support viable efficacy and safety profile for advancing development.

The rating upgrade from JMP Securities caused a lot of (Read More….)

Popular Blogger Makes the Case For Catalyst Pharmaceuticals

January 4, 2017: The popular SeekingAlpha blogger Hawkinvest, with over 5,000 followers, posted a positive article on Catalyst Pharmaceuticals today that got the stock moving higher. Hawkinvest writes…

Biotech and healthcare stocks underperformed in 2016 and that means this is a sector that could offer value and rebound potential in 2017. With all of this (Read More….)

Inotek Pharmaceuticals Powned Analysts, Crushing Losses

January 3, 2017: Canaccord Genuity, Roth Capital, and HC Wainwright/Rodman & Renshaw all scrambled for the exist in Inotek Pharmaceuticals after the company announced Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma fails to meet its primary endpoint. I am dropping coverage of the company, RIP.

December 20, 2016: Canaccord Genuity (

Novartis Alcon Receives FDA Approval For AcrySof

February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)

OvaScience Biotech Blogger Making Positive Tweet

December 29, 2016: OvaScience moving higher after popular biotechnology blogger makes positive comments on Twitter. @BioBreakthrough tweets: “Long 100,000 shares of $OVAS. Stock could double in early January as tax loss selling abates. ~ $4/share in cash, multiple 2017 catalysts.”

Long 100,000 shares of $OVAS. Stock could double in early January as (Read More….)

Omega Protein Could Benefit From NEJM Report

December 28, 2016: NEJM publishes article concluding that fish oil supplements during pregnancy reduces the risk of wheezing and asthma in offspring. This report could be a major catalyst for Omega Protein.

NEJM assessed the effect of supplementation with n-3 LCPUFAs (fish oil) in pregnant women on the risk of persistent wheeze and asthma in (Read More….)

The Ensign Group Purchases 15 Wisconsin Assisted Living Assets

December 27, 2016: The Ensign Group acquired the underlying real estate of fifteen assisted living operations located throughout Wisconsin. An Ensign subsidiary has been operating each facility since August 2015 under a lease with a purchase option.

The CEO said, “With our ownership of this real estate, we are excited about deepening our commitment to (Read More….)